<DOC>
	<DOCNO>NCT01213368</DOCNO>
	<brief_summary>Primary Objective : - To assess efficacy dronedarone versus placebo control ventricular rate patient permanent Atrial Fibrillation ( AF ) . Secondary Objective : - To assess safety tolerability dronedarone repeat oral dos 300 mg , 400 mg , 600 mg twice daily select population . - To document SR33589 SR35021 trough plasma level steady state .</brief_summary>
	<brief_title>Dose Ranging Study Dronedarone Control Ventricular Rate Japanese Patients With Permanent Atrial Fibrillation</brief_title>
	<detailed_description>The study period per patient approximatively 1 month broken follow : - Screening period 7 day , - Treatment period 14 day , - Follow-up period 10 day .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Patients age 20 year . Permanent Atrial Fibrillation [ AF ] ( define duration AF &gt; 6 month ) cardioversion consider rest ventricular heart rate ≥ 80 bpm screening . Exclusion criterion : Unstable angina pectoris . History torsades de pointes . Prolonged QT correct interval ( ≥ 500 m ) . Third degree atrioventricular block ( AVB ) screen ECG AF , documentation previous ECGs sinus rhythm PRinterval &gt; 0.28 sec high degree AVB ( 2nd degree high ) , significant sinus node disease ( document pause ≥ 3 sec ) without permanent pacemaker implant . Congestive Heart Failure ( CHF ) New York Heart Association classification ( NYHA ) class IV recent ( within 1 month prior randomization ) unstable NYHA class III . Treatment class I III antiarrhythmic drug . Patients treat amiodarone 4 week precede randomization . Clinically relevant haematologic , hepatic , gastrointestinal , renal , pulmonary , endocrinologic ( particular thyroid ) psychiatric disease . Hypokalemia hypomagnesemia must correct randomization . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>